Why the study?
Although the AHA PREVENT equations were developed for primary prevention, they incorporate factors relevant to HF; whether they predict clinical outcomes in HFpEF was unknown.
Do the PREVENT equations predict major adverse cardiovascular events in patients with HFpEF?
Population
434 patients aged 30 to 79 years with HFpEF (280 analyzed)
Comparison
PREVENT risk equations (PREV-CVD, PREV-HF, PREV-ASCVD)
Design
Prospective multicenter observational study cohort
Follow-up
Median 1384 days (IQR 882-1785)
Key result
The PREVENT equations independently predicted major adverse cardiovascular events in patients with HFpEF, with the PREV-CVD score showing a significant association (HR 1.04; 95% CI 1.02-1.07).
Authors
Loading...
May support risk stratification in HFpEF; extends PREVENT validation but remains hypothesis-generating and should not yet change practice.
Observational (n=280)
Yes
Do the PREVENT equations predict major adverse cardiovascular events in patients with HFpEF?
Effect estimate: HR 1.04 (95% CI 1.02-1.07)
p-value: p=0.00004
The PREVENT equations, originally designed for primary prevention, effectively predict major adverse cardiovascular events and heart failure hospitalizations in patients with HFpEF.
Iwakura et al. (2025) conducted an observational in Heart failure with preserved ejection fraction (HFpEF) (n=280). PREVENT equations was evaluated on Major adverse cardiovascular events (MACE), a composite of death, HF hospitalisation (HHF), and stroke (HR 1.04, 95% CI 1.02-1.07, p=0.00004). The PREVENT equations independently predicted major adverse cardiovascular events in patients with HFpEF, with the PREV-CVD score showing a significant association (HR 1.04; 95% CI 1.02-1.07).